Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
(2022, June 17)
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and still being evaluated in Phase 2 and Phase 3 clinical trials
AHK-Cu supports hair growth by improving blood flow to the follicle, while GHK-Cu helps with tissue repair and collagen care
It supports energy production through fatty acid metabolism, not through stimulants like caffeine
Cognitive function : NAD+ is involved in neuronal health and synaptic plasticity
US$ 21.46
US$ 28.76
US$ 20.89
